Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

Similar articles for PubMed (Select 21327637)

1.

Molecular analysis of melanoma-induced sentinel lymph node immune dysfunction.

Lee JH, Chen Y, Chan JL, Qian YW, Goydos JS.

Cancer Immunol Immunother. 2011 May;60(5):685-92. doi: 10.1007/s00262-011-0982-x. Epub 2011 Feb 16.

PMID:
21327637
2.

Cytokine expression and dendritic cell density in melanoma sentinel nodes.

Botella-Estrada R, Dasí F, Ramos D, Nagore E, Herrero MJ, Giménez J, Fuster C, Sanmartín O, Guillén C, Aliño S.

Melanoma Res. 2005 Apr;15(2):99-106.

PMID:
15846142
3.

Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients.

Speeckaert R, Vermaelen K, van Geel N, Autier P, Lambert J, Haspeslagh M, van Gele M, Thielemans K, Neyns B, Roche N, Verbeke N, Deron P, Speeckaert M, Brochez L.

Eur J Cancer. 2012 Sep;48(13):2004-11. doi: 10.1016/j.ejca.2011.09.007. Epub 2011 Oct 25.

PMID:
22033321
4.

Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus.

Hangalapura BN, Oosterhoff D, Aggarwal S, Wijnands PG, van de Ven R, Santegoets SJ, van den Tol MP, Hooijberg E, Pereboev A, van den Eertwegh AJ, Curiel DT, Scheper RJ, de Gruijl TD.

J Immunother. 2010 Sep;33(7):706-15. doi: 10.1097/CJI.0b013e3181eccbd4.

PMID:
20664356
5.

Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes.

Lee JH, Torisu-Itakara H, Cochran AJ, Kadison A, Huynh Y, Morton DL, Essner R.

Clin Cancer Res. 2005 Jan 1;11(1):107-12.

6.

Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content.

Vuylsteke RJ, Molenkamp BG, van Leeuwen PA, Meijer S, Wijnands PG, Haanen JB, Scheper RJ, de Gruijl TD.

Clin Cancer Res. 2006 May 1;12(9):2826-33.

7.

Immune cell profile of sentinel lymph nodes in patients with malignant melanoma - FOXP3+ cell density in cases with positive sentinel node status is associated with unfavorable clinical outcome.

Mohos A, Sebestyén T, Liszkay G, Plótár V, Horváth S, Gaudi I, Ladányi A.

J Transl Med. 2013 Feb 18;11:43. doi: 10.1186/1479-5876-11-43.

8.

Optimal detection of sentinel lymph node metastases by intraoperative radioactive threshold and molecular analysis in patients with melanoma.

Manca G, Romanini A, Pellegrino D, Borsò E, Rondini M, Orlandini C, Zucchi V, Pasqualetti F, Mariani G.

J Nucl Med. 2008 Nov;49(11):1769-75. doi: 10.2967/jnumed.108.055350. Epub 2008 Oct 16.

9.

Cytokine profiles of sentinel lymph nodes draining the primary melanoma.

Leong SP, Peng M, Zhou YM, Vaquerano JE, Chang JW.

Ann Surg Oncol. 2002 Jan-Feb;9(1):82-7.

PMID:
11833497
10.

Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer.

Mansfield AS, Heikkila PS, Vaara AT, von Smitten KA, Vakkila JM, Leidenius MH.

BMC Cancer. 2009 Jul 15;9:231. doi: 10.1186/1471-2407-9-231.

11.

Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival.

Brody JR, Costantino CL, Berger AC, Sato T, Lisanti MP, Yeo CJ, Emmons RV, Witkiewicz AK.

Cell Cycle. 2009 Jun 15;8(12):1930-4. Epub 2009 Jun 15.

12.

Multimarker reverse transcriptase-polymerase chain reaction assay in lymphatic drainage and sentinel node tumor burden.

Rutkowski P, Nowecki ZI, van Akkooi AC, Kulik J, Wanda M, Siedlecki JA, Eggermont AM, Ruka W.

Ann Surg Oncol. 2010 Dec;17(12):3314-23. doi: 10.1245/s10434-010-1142-9. Epub 2010 Jul 7.

13.

Mechanisms of local immunosuppression in cutaneous melanoma.

Polak ME, Borthwick NJ, Gabriel FG, Johnson P, Higgins B, Hurren J, McCormick D, Jager MJ, Cree IA.

Br J Cancer. 2007 Jun 18;96(12):1879-87. Epub 2007 Jun 12.

14.

Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma.

Lee JR, Dalton RR, Messina JL, Sharma MD, Smith DM, Burgess RE, Mazzella F, Antonia SJ, Mellor AL, Munn DH.

Lab Invest. 2003 Oct;83(10):1457-66.

PMID:
14563947
15.

Effect of melanoma on immune function in the regional lymph node basin.

Negin B, Panka D, Wang W, Siddiqui M, Tawa N, Mullen J, Tahan S, Mandato L, Polivy A, Mier J, Atkins M.

Clin Cancer Res. 2008 Feb 1;14(3):654-9. doi: 10.1158/1078-0432.CCR-07-1577.

16.

Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection.

Witkiewicz A, Williams TK, Cozzitorto J, Durkan B, Showalter SL, Yeo CJ, Brody JR.

J Am Coll Surg. 2008 May;206(5):849-54; discussion 854-6. doi: 10.1016/j.jamcollsurg.2007.12.014. Epub 2008 Mar 4.

PMID:
18471709
17.

Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes.

Porter GA, Abdalla J, Lu M, Smith S, Montgomery D, Grimm E, Ross MI, Mansfield PF, Gershenwald JE, Lee JE.

Ann Surg Oncol. 2001 Mar;8(2):116-22.

PMID:
11258775
18.

Indoleamine 2,3-dioxygenase+ cells correspond to the BDCA2+ plasmacytoid dendritic cells in human melanoma sentinel nodes.

Gerlini G, Di Gennaro P, Mariotti G, Urso C, Chiarugi A, Pimpinelli N, Borgognoni L.

J Invest Dermatol. 2010 Mar;130(3):898-901. doi: 10.1038/jid.2009.307. Epub 2009 Oct 15. No abstract available.

19.

The predictive value of the sentinel lymph node in malignant melanomas.

Bachter D, Michl C, Büchels H, Vogt H, Balda BR.

Recent Results Cancer Res. 2001;158:129-36.

PMID:
11092040
20.

Reliability and accuracy of sentinel node biopsy in cutaneous malignant melanoma.

Carcoforo P, Soliani G, Bergossi L, Basaglia E, Virgili AR, Pagani W, Pozza E, Feggi LM.

Tumori. 2002 May-Jun;88(3):S14-6.

PMID:
12365371
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk